Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia.

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the world, with treatment outcomes improving dramatically in the past several decades due to the combined usage of multiple drugs and sophisticated therapeutic protocols.[1][1] Thiopurine (e.g., 6-mercaptopurine) is primarily